Johnson & Johnson (NYSE:JNJ) is one of Navellier’s top long-term stock picks. On May 12, Johnson & Johnson reaffirmed its push for opportunities in the treatment of calcified coronary artery disease, which affects about 315 million people worldwide. The company unveiled the Shockwave C2 Aero Coronary IVL Catheter, a next-generation intravascular lithotripsy catheter.
Copyright: moovstock / 123RF Stock Photo
An upgrade to the Shockwave C2+, the lithotripsy catheter features improved deliverability, enhanced lesion-crossing capabilities, and new repositioning functions. It also leverages ultrasonic acoustic pressure to disrupt plaque in coronary arteries. The catheter also comes with a more flexible shaft, a balloon, and marker bands to navigate tortuous arteries with ease.
With a working length of 138 centimeters and two emitters integrated into a balloon, the catheter can deliver up to 120 pulses and 240 shockwaves. While the device is currently available only in the US and Japan, Johnson & Johnson is working on making it available in Canada and Europe.
Johnson & Johnson is a global healthcare company that researches, develops, and manufactures innovative medicines (pharmaceuticals) and medical technology (MedTech) products. It focuses on treating complex diseases, advancing surgical care, and improving patient outcomes in areas such as cancer, immunology, and orthopedics.
READ NEXT: Billionaire Steve Cohen’s 10 Large-Cap Stock Picks with Highest Upside Potential and 12 Best Uranium Stocks to Buy According to Wall Street Analysts.
Hedge Fund Resource Center